DNA topoisomerases I & II cleavage sites in the type 1 human immunodeficiency virus (HIV-1) DNA promoter region.
Topoisomerase sites were mapped in the 5'-long terminal repeat of HIV-1 DNA by agarose and sequencing gel electrophoresis. Topoisomerase II sites were observed in the absence and presence of teniposide and amsacrine in the transcription initiation region and the TATA box, consistent with a possible role of topoisomerase II in transcription. The NF-kB and Sp1 regions were poorly cleaved. Topoisomerase I sites were relatively unfrequent even in the presence of camptothecin. They were absent in the core promoter and were concentrated in the TAR and the upstream region near the junction with the host DNA.
Pommier
Y
Y
Laboratory of Molecular Pharmacology, National Cancer Institute, NIH, Bethesda, MD 20892.
Poddevin
B
B
Gupta
M
M
Jenkins
J
J
D000677:Amsacrine / Q000494:pharmacology; D000818:Animals; D001665:Binding Sites / Q000235:genetics; D002166:Camptothecin / Q000494:pharmacology; D002874:Chromosome Mapping; D004264:DNA Topoisomerases, Type I / Q000378:metabolism*; D004250:DNA Topoisomerases, Type II / Q000378:metabolism*; D004279:DNA, Viral / Q000235:genetics* / Q000378:metabolism; D005814:Genes, Viral; D016325:HIV Long Terminal Repeat; D015497:HIV-1 / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D051379:Mice; D016328:NF-kappa B / Q000378:metabolism; D011401:Promoter Regions, Genetic; D016329:Sp1 Transcription Factor / Q000378:metabolism; D016385:TATA Box / Q000235:genetics; D013713:Teniposide / Q000494:pharmacology
D004279:DNA, Viral; D016328:NF-kappa B; D016329:Sp1 Transcription Factor; D000677:Amsacrine; D013713:Teniposide; D004264:DNA Topoisomerases, Type I; D004250:DNA Topoisomerases, Type II; D002166:Camptothecin